Seeking Alpha

Mike Havrilla » Comments » Single Comment

  • BioMed News: Antigenics, Shire, King Pharma, Delcath Systems [View article]
    dreamdivers, you can review my article archives and easily distinguish between information provided on upcoming data points, regulatory decisions, and clinical catalysts as compared to stocks that I own or write commentaries on.

    AGEN is tracked in the FDA Calendar database because it will release an update next year from the patient registry which will impact the stock price. I have never written an opinion piece on AGEN or recommended that anyone buy the stock and have only pointed it out for the pending catalysts in the form of the EMEA decision and clinical data update.

    On Oct 21 09:17 PM dreamdivers wrote:

    > So in your article today you devote an entire first paragraph to
    > summarizing the "positive" data, which you later admit comes only
    > from the company data mining retrospectively? Meanwhile, you reluctantly
    > admit only when directly questioned that pivotal trials in both RCC
    > and melanoma failed? You guys really should be ashamed, why not just
    > put on cheerleader skirts and make it official.
    Oct 21 21:37 pm |Rating: +6 -2
All Comments by Mike Havrilla »
Comments by Ticker
AAWW, ABIO, ABMD, ABT, ABX, ACAD, ACCP.OB, ACHN, ACLI, ACOR, ACTC.PK, ACUR, ACUS, ADLR, ADLS, ADLS.OB, AEZS, AFFX, AGEN, AGF, AGN, AHBIF.PK, AIQ, AIS, ALEX, ALGT, ALKS, ALO, ALPMF.PK, ALTH, ALV, ALVR, AMAG, AMGN, AMR, AMX, ANDS, ANPI, APPA, APPX, ARDM.OB, ARIA, ARKTF.PK, ARNA, ARQL, ARYX, ASO, ASTM, ATHX, ATSI,
Mike Havrilla's
Comments Stats
172 comments
Rating: 27 (48 - 21 )